MCL Research Must Refocus on Sequencing, Goy Says – Targeted Oncology
Targeted OncologyMCL Research Must Refocus on Sequencing, Goy SaysTargeted OncologyFor example, ZUMA-2, a phase II, multicenter, open-label study is currently evaluating the efficacy of the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ci… Continue reading
